(NASDAQ: GH) Guardant Health's forecast annual revenue growth rate of 16.07% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.08%.
Guardant Health's revenue in 2025 is $902,569,000.On average, 28 Wall Street analysts forecast GH's revenue for 2025 to be $119,485,691,961, with the lowest GH revenue forecast at $109,316,696,901, and the highest GH revenue forecast at $122,883,759,721.  On average, 29 Wall Street analysts forecast GH's revenue for 2026 to be $146,963,909,774, with the lowest GH revenue forecast at $131,208,773,649, and the highest GH revenue forecast at $158,307,607,784.  
In 2027, GH is forecast to generate $178,852,305,291 in revenue, with the lowest revenue forecast at $148,980,567,198 and the highest revenue forecast at $217,294,837,436.